Kolexia
Mazard Thibault Gastro-entérologie
Mazard Thibault
Gastro-entérologie
Icm Montpellier
Montpellier, France
164 Activités
216 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Métastase tumorale Adénocarcinome Tumeurs du côlon Cellules tumorales circulantes Carcinomes Tumeurs du pancréas Instabilité des microsatellites Tumeurs du foie

Collaborateurs

Voir plus
Ychou Marc
Ychou Marc
Icm Montpellier, Montpellier, France
Assenat Eric
Assenat Eric
Icm Montpellier, Montpellier, France
Samalin Scalzi Emmanuelle
Samalin Scalzi Emmanuelle
Icm Montpellier, Montpellier, France
Portales Fabienne
Portales Fabienne
Icm Montpellier, Montpellier, France

Industries

Voir plus
B3TSI
44 collaboration(s)
Dernière en 2023
A+A
14 collaboration(s)
Dernière en 2023
IQVIA
12 collaboration(s)
Dernière en 2023
Servier
9 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors: Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Essai Clinique (Merus N.V.)   01 mars 2024
FOLFIRINOX-R: Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With RAS-mutated Metastatic Colorectal Cancer: a Dose-escalation, Phase I/II Trial
Essai Clinique (Institut du Cancer de Montpellier)   08 février 2024
Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   16 janvier 2024
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
British journal of cancer   15 décembre 2023
625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
NIPISAFE: Analysis of the Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer: A GERCOR Open-label, Randomized, Non-comparative, Two-stage Phase II Trial (NIPISAFE).
Essai Clinique (BMS)   27 septembre 2023
NIPICOL: Interest of iRECIST Radiological Assessment for Disease Control Rate (DCR) for Evaluation of Patients With Metastatic Colorectal Cancer dMMR and/or MSI Treated With Nivolumab and Ipilimumab. A GERCOR Open-label Phase II Study NIPICOL C17-01
Essai Clinique (BMS)   26 septembre 2023
GRECCAR 14 - a multicentric, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: Study protocol.
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland   11 septembre 2023
PANIRINOX: Phase II Randomized Study Comparing FOLFIRINOX + Panitumumab Versus mFOLFOX6 + Panitumumab in Metastatic Colorectal Cancer Patients Selected by RAS and B-RAF Status From Circulating DNA Analysis
Essai Clinique (Unicancer)   30 août 2023